Treanda for indolent Non-Hodgkin Lymphoma


( Last Updated : December 14, 2012)
Generic Name:
Bendamustine hydrochloride
Project Status:
Complete
Therapeutic Area:
Non-Hodgkin Lymphoma and Mantle Cell Lymphoma
Manufacturer:
Lundbeck Canada Inc.
Brand Name:
Treanda
Project Line:
Reimbursement Review
Project Number:
PC0010-000
NOC Date:

Details


Strength:
25 mg/vial and 100 mg/vial
Tumour Type:
Lymphoma
Indications:
Non-Hodgkin lymphoma (NHL)
Funding Request:
For patients with indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma (first line and relapse/refractory)
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Lundbeck Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.